Document:

First Amendment to License Agreement, dated as of December 15, 2002

  
 Exhibit 10.40

  
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR AXON 
 GROWTH TECHNOLOGIES 
  
 THIS FIRST AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH
TECHNOLOGIES (the “Amendment”) is made and entered into effective as of December 15, 2002 (the “Amendment Effective Date”), by and between RENOVIS,
INC., a Delaware corporation (“Renovis”) having its place of business at 270 Littlefield Avenue, South San Francisco, CA 94080, and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) whose legal address is 1111 Franklin Street, 12 Floor, Oakland, California 94607-5300, acting through its Office of Technology Licensing at the
University of California, Berkeley, California 94720-1620. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as “Parties”. 
  
 RECITALS 
  
 A. Renovis and The Regents entered into an Exclusive License Agreement for
Axon Growth Technologies (the “Agreement”) effective June 1, 2001, whereby The Regents granted to Renovis an exclusive license to certain axon growth technologies potentially useful for discovering and developing therapeutic drugs.

  
 B. The Parties desire to amend the terms of the Agreement as
provided in this Amendment to modify certain payment obligations that Renovis owes to The Regents in consideration for issuance to The Regents of sixty thousand (60,000) shares of Renovis’ common stock, to be granted under that certain Stock
Purchase Agreement entered into between the Parties concurrently with this Agreement. 
  
 NOW, THEREFORE, the Parties agree as follows: 
  

	1.	AMENDMENT OF THE AGREEMENT 

  
 The Parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective
Date. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following provisions. Where the Agreement is not explicitly
amended, the terms of the Agreement will remain in force. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement. 
  
 1.1 Amendment of Article 2 of the Agreement. A new Article 2.8 is
hereby added to Article 2 of the Agreement, reading in its entirety as follows: 
  
 “2.8 “[*] AGREEMENT” means the exclusive license between LICENSEE and REGENTS for [*]/Small Molecule, and [*] Protein
Technologies, UC Case nos. 1993-300, 1996-217, 1997-288, 1999-011, 1999-112,1999-244, dated as of 11/25, 2002.” 
  

 1. 

 1.2 Amendment of Article 2.4 of the Agreement. Article 2.4 of the Agreement is hereby amended to
read in its entirety as follows: 
  
 “2.4
“NET ROYALTIES” shall mean royalty payments due to LICENSEE on sublicensee’s sales of LICENSED PRODUCTS or LICENSED METHODS; but excluding, minimum annual royalty payments, and the transfer price of LICENSED PRODUCTS
supplied at less than one hundred percent (100%) of fully burdened manufacturing costs paid by such sublicensee to LICENSEE on sales of LICENSED PRODUCTS.” 
  

1.3 Amendment of Article 2.6 of the Agreement. 
  
 (a) Article 2.6 of the Agreement is hereby amended to delete the phrase “NET ROYALTIES” from the first sentence of such
Article 2.6. 
  
 (b) Article 2.6 of
the Agreement is hereby amended to replace the phrase “Section 6.8” with the phrase “Article 4.2” in the second paragraph of such Article 2.6. 
  
 1.4 Amendment of Article 4.2 of the Agreement. 
  
 (a) Subclause (a) and subclause (b) of Article 4.2 the Agreement are hereby amended to replace the
phrase “SUBLICENSING FEES” with the phrase “SUBLICENSE FEES” in each subclause. 
  
 (b) A new Article 4.2(c) is hereby added to the Agreement, reading in its entirety as follows: 
  
 “(c) The greater of: (i) [*] percent ([*]%) of NET
ROYALTIES due to LICENSEE under any sublicense agreement or (ii) [*] percent ([*]%) of Net Sales invoiced or otherwise charged by such sublicensee for such sales; provided that, if LICENSEE must pay to REGENTS, pursuant to the terms of the
[*] AGREEMENT, a share of the payments received from such sublicense agreement, then the payment otherwise due by LICENSEE to REGENTS hereunder subclause (i) above shall be reduced to [*] percent ([*]%) of NET ROYALTIES due to LICENSEE under any
sublicense agreement, or, as applicable, the payment otherwise due under subclause (ii) above shall be reduced by the amount of such payment payable to The Regents under the [*] AGREEMENT, provided further, that, in no event shall the
payment described in subclause (ii) above be reduced to less than [*] percent ([*]%) of Net Sales due to LICENSEE under such sublicense agreement. If the NET ROYALTIES paid to LICENSEE by any sublicensee are lower than [*] percent ([*]%) of Net
Sales actually received by a sublicensee, then LICENSEE and REGENTS shall negotiate in good faith a new fair and reasonable rate for NET ROYALTIES (which shall be less than the above rate in subclause (ii)).” 
  

 2. 

 1.5 Amendment of Article 6.1 of the Agreement. The second sentence of Article 6.1 is hereby
amended to read in its entirety as follows: 
  
 “The minimum
annual royalty shall be creditable against royalties due pursuant to Article 6.2 on NET SALES occurring in that calendar year and against payments due pursuant to Article 4.2 for amounts received during that calendar year.” 
  

	2.	MISCELLANEOUS 

  
 2.1 Full Force and Effect. This Amendment amends the terms of the Agreement and is deemed incorporated into, and governed by all other terms of,
the Agreement. The provisions of the Agreement, as amended by this Amendment, remain in full force and effect. 
  
 2.2 Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, the Parties have executed this Amendment in duplicate originals by their authorized officers as of the Effective Date. 
  

	 RENOVIS, INC.
	 	 	 	THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA
					
	By:	 	 /s/    LYNNE
ZYDOWSKY        

	 	 	 	By:	 	 /s/    WILLIAM A.
HOSKINS        

					
	 Title:
	 	S.V.P, Corporate Development	 	 	 	 Title:
	 	Director, UCB Office of Technology Licensing
					
	 Date:
	 	12/16/02	 	 	 	 Date:
	 	Dec 18, 2002

  

 3.Second Amendment to License Agreement, dated as of December 23, 2003

  
 Exhibit 10.41

  
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIES 
  
 THIS SECOND AMENDMENT TO THE
EXCLUSIVE LICENSE AGREEMENT FOR AXON GROWTH TECHNOLOGIES (the “Amendment”) is made and entered into
effective as of December 23rd, 2003 (the “Amendment Effective Date”), by and between
RENOVIS, INC., a Delaware corporation (“Renovis”) having its place of business at Two Corporate Drive, South San Francisco, CA 94080, and THE REGENTS
OF THE UNIVERSITY OF CALIFORNIA, a California corporation (“The Regents”) whose legal address is 1111 Franklin Street, 12 Floor, Oakland,
California 94607-5300, acting through its Office of Technology Licensing at the University of California, Berkeley, California 94720-1620. Renovis and The Regents may be referred to herein as a “Party” or, collectively, as
“Parties”. 
  
 RECITALS

  
 A. Renovis and The Regents entered into an Exclusive
License Agreement for Axon Growth Technologies (the “Agreement”) effective June 1, 2001, whereby The Regents granted to Renovis an exclusive license to certain axon growth technologies potentially useful for discovering and
developing therapeutic drugs. 
  
 B. Effective December 15, 2002,
the Parties amended the Agreement by that First Amendment to the Exclusive License Agreement for Axon Growth Technologies. 
  
 C. The Parties desire to further amend the terms of the Agreement as provided in this Amendment to clarify the rights and obligations of Renovis with
respect to sublicensing and to provide Renovis’ sublicensee(s) with certain rights to further sublicense under the Agreement. 
  
 NOW, THEREFORE, the Parties agree as follows: 
  

	1.	AMENDMENT OF THE AGREEMENT 

  
 The Parties hereby agree to amend the terms of the Agreement as provided below, effective as of the Amendment Effective
Date. To the extent that the Agreement is explicitly amended by this Amendment, the terms of the Amendment will control where the terms of the Agreement are contrary to or conflict with the following provisions. Where the Agreement is not explicitly
amended, the terms of the Agreement will remain in force. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement. 
  
 1.1 Amendment to Article 2.5. A new sentence is added to the end of
Article 2.5 as follows: 
  
 “Also for purposes of this
definition, sales of LICENSED PRODUCTS or LICENSE METHODS by and between LICENSEE and a SUBLICENSEE, or from a SUBLICENSEE to its further SUBLICENSEE(s), are excluded from this definition of NET SALES, provided that the final sales of LICENSED
PRODUCTS or LICENSE METHODS by such SUBLICENSEE(s) to third parties who are not AFFILIATEs or SUBLICENSEEs are properly included in NET SALES.” 
  

 1.2 Amendment to Article 2.7. A new sentence is added to the end of Article 2.7 as follows:

  
 “When used in connection with a SUBLICENSEE, the term
“AFFILIATE” shall have the same meaning as set forth in this Article but solely with respect to that SUBLICENSEE rather than LICENSEE.” 
  
 1.3 New Article 2.9. A new Article 2.9 is hereby added to the Agreement as follows: 
  
 “2.9 “SUBLICENSEE” or “sublicensee”
means any person(s) or entity(ies) to whom any of the license rights granted to LICENSEE hereunder are sublicensed by LICENSEE, and shall include any further sublicensee to a SUBLICENSEE.” 
  
 1.4 Amendment of Article 4.1(d). Article 4.1(d) of the
Agreement is hereby deleted and replaced in its entirety as follows: 
  
 “4.1(d) A SUBLICENSEE shall have the right to grant further sublicenses to its AFFILIATE(s) and/or third parties to the extent SUBLICENSEE deems such sublicenses are commercially reasonable, useful or necessary for the development
and/or commercialization of LICENSED PRODUCTS or LICENSED METHODS in accordance with this AGREEMENT; provided that (i) each such sublicense is subject to a written sublicense agreement and is bound by all of the applicable terms, conditions,
obligations, restrictions and other covenants of this AGREEMENT that protect or benefit the REGENTS’, HHMI’s (and, if applicable, the U.S. Government’s and other sponsors’) rights and interests; and (ii) SUBLICENSEE shall, within
30 days of issuing any further sublicenses, furnish to REGENTS, subject to any confidentiality provisions with third parties, all material terms of any such sublicenses pertaining to the REGENTS and/or HHMI’s interests, including the
SUBLICENSEE name and address.” 
  
 1.5 New Article
4.7. A new Article 4.7 is hereby added to the Agreement as follows: 
  
 “4.7 In the event that a SUBLICENSEE needs to grant further sublicenses to its AFFILIATES and/or other third parties, it shall have the right to do so as deemed commercially reasonable or necessary by SUBLICENSEE
for the development and/or commercialization of LICENSED PRODUCTS or LICENSED METHODS in accordance with this AGREEMENT. All such further sublicenses shall comply with each of the applicable requirements for sublicensing set forth in this AGREEMENT
as if it were a sublicense from LICENSEE to a SUBLICENSEE. In order to establish all amounts owed hereunder, LICENSEE covenants that it shall require each SUBLICENSEE (and shall require each SUBLICENSEE to require the same from each further
SUBLICENSEE) to report to LICENSEE all information (with the same frequency) that LICENSEE is obligated to provide to REGENTS hereunder or necessary for LICENSEE to satisfy its obligations to REGENTS under Article 4 and Article 6, and LICENSEE shall
make such reports available to the REGENTS. For the avoidance of doubt, each further SUBLICENSEE shall have the right to grant further 

  

 
sublicenses in accordance with the terms of this Article 4.7 as if it were a direct SUBLICENSEE of LICENSEE.” 
  

	2.	MISCELLANEOUS 

  
 2.1 Full Force and Effect. This Amendment amends the terms of the Agreement and is deemed incorporated into, and governed by all other terms
of, the Agreement. The provisions of the Agreement, as amended by this Amendment, remain in full force and effect. 
  
 2.2 Counterparts. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
  
 IN WITNESS WHEREOF, the Parties have executed this Amendment in duplicate originals by their authorized officers as of the Effective Date. 
  

	RENOVIS, INC.	 	 	 	THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA
					
	By:	 	 /s/    JOHN A.
KOLLINS        

	 	 	 	By:	 	 /s/    ILLEGIBLE        

					
	 Title:
	 	VP Business Development	 	 	 	 Title:
	 	Director, UCB OTL
					
	 Date:
	 	 12/23/2003
	 	 	 	 Date:
	 	 12/23/03

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]